Triple negative breast cancer (TNBC) is one of the most aggressive and lethal subtype of breast cancer (BC) and it covers 15-20% of overall BC diagnoses. While effective targetable therapy has been developed for subtypes expressing the estrogen, progesterone or Her2Neu receptors, TNBC lack these therapeutic targets. Thus, TNBC patients suffer from a dismal clinical prognosis associated with high metastatic burden. Therefore, there is an urgent clinical need to develop effective treatments for combating TNBC. Over the last decade, immunotherapy has become increasingly impactful owing to development of several promising combinational strategies for cancer treatment. Many experimental evidence suggest that the combination of immunotherapy with radiotherapy (RT) is a rational strategy for hard-to-treat cancers as it induces a substantive immunogenic effect, necessary to reprogram the tumor immune microenvironment.